Sovleplenib(Synonyms: HMPL-523)


Sovleplenib (Synonyms: HMPL-523)

Sovleplenib (HMPL-523) 是一种高效的、可口服的选择性 SYK 抑制剂,IC50 为 25 nM。具有抗肿瘤活性。Sovleplenib 可用于免疫性血小板减少症(ITP)的研究。

Sovleplenib(Synonyms: HMPL-523)

Sovleplenib Chemical Structure

CAS No. : 1415792-84-5

规格 价格 是否有货
5 mg ¥6800 询问价格 & 货期
10 mg ¥11000 询问价格 & 货期

* Please select Quantity before adding items.


Sovleplenib (HMPL-523) is a highly potent, orally available and selective SYK inhibitor with an IC50 of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP)[1].

IC50 & Target


(In Vitro)

Sovleplenib (HMPL-523) inhibits SYK, FLT3, KDR, LYN, FGFR2, and AUR A with IC50s of 0.025, 0.063, 0.390, 0.921, 3.214, 3.969 μM, respectively[1].
Sovleplenib (HMPL-523) blocks phosphorylation of BLNK, downstream protein of Syk, in human mantle cell line REC-1 and human plasma cell line ARH-7777 with IC50s of 0.105 µM and 0.173 μM, respectively[2].
Sovleplenib also inhibits cell viability of Ba/F3 Tel-Syk with the IC50 of 0.033 μM[2].
Sovleplenib also increases the apoptotic rate of REC-1 cells[2].
Sovleplenib shows the synergistic activities on killing human diffused large B cell lymphoma (DLBCL) in combination with other drugs such as BTK inhibitor, PI3Kδ inhibitors and Bcl2 family inhibitor[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

(In Vivo)

Sovleplenib (HMPL-523) shows anti-tumor activity in vivo. Sovleplenib (100 mg/kg) inhibits tumor growth in REC-1 subcutaneous xenograft model[1].
Sovleplenib (HMPL-523; 100 mg/kg; daily oral administration) shows potent anti-tumor activity in B cell lymphoma REC-1 (TGI: 59%) in Syk dependent xenograft models [2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Balb/c nude mice bearing subcutaneously implanted REC-1 cells or intravenously injected BA/F3 cells or BA/F3 TEL-SYK cells[1]
Dosage: 10 and 100 mg/kg
Administration: q.d.; for 8 days
Result: Inhibited tumor growth in REC-1 subcutaneous xenograft model at 100 mg/kg.








Room temperature in continental US; may vary elsewhere.


Please store the product under the recommended conditions in the Certificate of Analysis.

  • [1]. Su WG, et al. Preparation of pyridopyrazine derivatives for use as Syk inhibitors. WO2012167733 A1.

    [2]. Na Yang, et al. HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo. Blood (2016) 128 (22): 3970.